TheProfitWatch

VRDN - Viridian Therapeutics, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
29.4 0.97 (3.3%) -0.03 (-0.1%) -0.03 (-0.1%) -0.23 (-0.75%) 0.08 (0.27%) 1.06 (3.62%) 0.0 (0.0%) 0.48 (1.66%)

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Market

Earnings & Ratios

Basic EPS:
Diluted EPS:
Basic P/E:
Diluted P/E:
RSI(14) 1m:
48.53
VWAP:
30.39
RVol:

Events

Period Kind Movement Occurred At

Related News